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Zinc (Zn)-deficiency (ZD) is implicated in the pathogenesis of human oral-esophageal cancers. Previously, we showed that in ZD
mice genetic deletion of cyclooxygenase-2 (Cox-2) enhances N-nitrosomethylbenzylamine-induced forestomach carcinogenesis.
By contrast, Cox-2 deletion offers protection in Zn-sufficient (ZS) mice. We hypothesize that ZD activates pathways insensitive
to COX-2 inhibition, thereby promoting carcinogenesis. This hypothesis is tested in a Cox-2
2/2 mouse tongue cancer model
that mimics pharmacologic blockade of COX-2 by firstly examining transcriptome profiles of forestomach mucosa from Cox-2
2/2
and wild-type mice on a ZD vs. ZS diet, and secondly investigating the roles of identified markers in mouse forestomach/tongue
preneoplasia and carcinomas. In Cox-2
2/2 mice exposed to the tongue carcinogen 4-nitroquinoline 1-oxide, dietary ZD elicited
tongue/esophagus/forestomach carcinomas that were prevented by ZS. The precancerous ZD:Cox-2
2/2 vs. ZS:Cox-2
2/2
forestomach had an inflammatory signature with upregulation of the proinflammation genes S100a8 and S100a9.
Bioinformatics analysis revealed overrepresentation of inflammation processes comprising S100a8/a9 and an nuclear factor
(NF)-jB network with connectivity to S100A8. Immunohistochemistry revealed co-overexpression of S100A8, its heterodimeric
partner S100A9, the receptor for advanced glycation end-products (RAGE), NF-jB p65, and cyclin D1, in ZD:Cox-2
2/2
forestomach/tongue preneoplasia and carcinomas, evidence for the activation of a RAGE-S100A8/A9 inflammatory pathway.
Accumulation of p53 in these carcinomas indicated activation of additional inflammatory pathways. Zn-replenishment in
ZD:Cox-2
2/2mice reversed the inflammation and inhibited carcinogenesis. Thus, ZD activates alternative inflammation-
associated cancer pathways that fuel tumor progression and bypass the antitumor effect of Cox-2 ablation. These findings have
important clinical implications, as combination cancer therapy that includes Zn may improve efficacy.
Oral-esophageal squamous cell carcinomas (SCCs) are a
major cause of cancer deaths worldwide.
1 Oral cancer, the
major site being the tongue, causes a high mortality rate
because of frequent development of a second primary esoph-
ageal cancer because of ﬁeld cancerization effects.
2 Risk fac-
tors include alcohol consumption, tobacco and human papil-
lomavirus (HPV).
3 The incidence of oral cancer is increasing,
particularly in young adults without documented risk
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3 Epidemiologic and clinical studies have long impli-
cated zinc (Zn)-deﬁciency (ZD) in the pathogenesis of oral-
esophageal cancers in many populations.
4–6 ZD is associated
with increased tumor size and poor disease prognosis.
4,7
Zn is required for the activity of many enzymes, for
proper immune function, and for the conformation of many
transcription factors that control cell proliferation, apoptosis,
and signaling pathways.
8,9 Zn is known to undergo rapid
ligand exchange reactions and is used as an information car-
rier in signal transduction pathways similar to calcium.
10
Consequently, ZD predisposes to disease by adversely affect-
ing immune system, by increasing oxidative stress, and by
increasing the generation of inﬂammatory cytokines.
11
Although the role of ZD as a causative factor of disease and
as a determinant in disease progression is gaining attention,
12
the mechanisms underlying its protumorigenic effect, how-
ever, remain unclear.
In the rat, a ZD diet creates a precancerous condition in
the upper digestive tract, including tongue, esophagus and
forestomach (an expanded lower esophagus), by inducing
proliferation
13 and gene expression changes, including over-
expression of cyclooxygenase-2 (Cox-2) and the proinﬂamma-
tion-genes S100 calcium binding protein a8 (S100a8) and a9
(S100a9).
13,14 ZD rats rapidly develop esophageal tumors
after a single exposure to the environmental carcinogen
N-nitrosomethylbenzylamine (NMBA)
15 and concurrent tongue,
esophageal and forestomach tumors with exposure to the
tongue carcinogen 4-nitroquinoline 1-oxide (NQO).
13 Zn-
replenishment (ZR) reverses cell proliferation, corrects gene
expression and inhibits carcinogenesis.
14–16
Targeted therapies that block molecules crucial to tumor
growth are being explored in attempts to prevent or cure
cancer.
17 The rationale for targeting the COX-2 pathway is
supported by numerous studies. COX-2 is overexpressed in
many human cancers, including esophageal and tongue
SCC.
18,19 COX-2 catalyzes the formation of prostaglandins
and is induced by factors implicated in carcinogenesis,
including growth factors, inﬂammatory stimuli, oncogenes
and tumor promoters.
20 The report that deletion of the Cox-
2 gene in Apc knockout mice greatly reduces intestinal polyp
formation provides genetic evidence that COX-2 plays a key
role in tumorigenesis.
21 COX-2 selective inhibitors, celecoxib
in particular, are being tested in clinical trials for the preven-
tion of several cancers,
22 including esophageal cancer.
23
Although such targeted therapies have shown promising
results in several cancers, their efﬁcacy in oral-esophageal
cancer has been limited.
24
Our previous work showed that in ZD rats pharmacologic
COX-2 inhibition by the drug celecoxib did not prevent
tongue carcinogenesis, and in ZD mice genetic Cox-2 deletion
actually enhanced NMBA-induced forestomach tumorigene-
sis.
16 Aside from the result that ZD:Cox-2
 /  mouse forest-
omach overexpressed leukotriene A4 hydrolase protein, indi-
cating a shift of arachidonic acid to the 5-lipoxygenase
pathway, mechanisms underlying this effect of ZD were not
elucidated. We hypothesized that ZD adversely affects treat-
ment outcome by stimulating pathways not inhibited by the
pharmacologic blockade of COX-2. We tested this hypothesis
in a ZD:Cox-2
 /  mouse oral-esophageal cancer model that
mimics pharmacologic COX-2 blockade, using techniques
that included transcriptome proﬁling, bioinformatics analyses,
and investigation of the pathobiological roles of identiﬁed
markers in murine tongue/forestomach preneoplasia and
neoplasia.
Material and Methods
Mice, diets and carcinogens
We bred heterozygous B6;129S7-Ptgs2
tm1Jed/J males to
females (Jackson Laboratory, Bar Harbor, ME) to generate
Cox-2
 / , Cox-2
þ/  and Cox-2
þ/þ (WT) littermates.
16 Cus-
tom-formulated ZD and Zn-sufﬁcient (ZS) diets (Harlan
Teklad, Madison, WI) were identical except for the Zn con-
tent.
16 NQO was from Wako Chemicals (Richmond, VA)
and NMBA from Midwest Research Institute (Kansas City,
MI).
NQO-induced tongue carcinogenesis
The mouse studies were approved by The Ohio State Univer-
sity Animal Use Committee. Four-week old littermates were
fed ZD or ZS diets to form six groups, namely, ZD:Cox-2
 / 
(n ¼ 14), ZD:Cox-2
þ/  (n ¼ 46), ZD:WT (n ¼ 19), ZS:Cox-
2
 /  (n ¼ 16), ZS:Cox-2
þ/  (n ¼ 37) and ZS:WT (n ¼ 25).
After 4 weeks the mice were administered NQO in deionized
water for tongue tumor induction (20 ppm for 19 weeks fol-
lowed by 30 ppm for 7 weeks). At 26 weeks, the animals
were sacriﬁced for tumor incidence analysis.
Expression proﬁling and related studies
Weanling Cox-2
 /  and Cox-2
þ/þ mice were fed ZD or ZS
diets to form four groups, namely, ZD:Cox-2
 /  (n ¼ 20),
ZS:Cox-2
 /  (n ¼ 12), ZD:WT (n ¼ 12) and ZS:WT (n ¼
12). After 9 weeks, 8 ZD:Cox-2
 /  mice were switched to a
ZS diet to form the ZR:Cox-2
 /  group. After a week, all
mice were sacriﬁced. This experimental regimen produced
unbridled cell proliferation in ZD:Cox-2
 /  forestomach.
16
Tongue and forestomach were isolated and cut into two por-
tions. One portion was formalin-ﬁxed and parafﬁn-embedded
for immunohistochemical (IHC) studies. Forestomach epithe-
lia for expression proﬁling studies were prepared from the
remaining portion by using a blade to strip off the submuco-
sal layers and snap-frozen in liquid nitrogen.
We performed expression proﬁling of forestomach mucosa
from ZD:Cox-2
 / , ZS:Cox-2
 / , ZD:WT mice and ZS:WT
mice after 10 weeks of ZD or ZS diets (n ¼ 4 mice/group),
using GeneChipV R Mouse Genome 430 2.0 Array (Affymetrix,
Santa Clara, CA). Total RNA was extracted from forestomach
mucosa using TRIZOL reagent (Invitrogen, Carlsbad, CA).
Five micrograms of total RNA was reverse transcribed into
cDNA followed by in vitro transcription and labeling to
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the arrays as described.
14
Expression data analysis
We used the Class Comparison analysis of BRB-Array Tools
software version 3.7.0 (Biometric Research Branch, NCI) to
identify differentially expressed mRNAs. The Robust Multichip
Average method was performed. The array data were submit-
ted to ArrayExpress (Accession number: E-TABM-778).
Gene ontology and pathway analyses
We used DAVID (Database for Annotation, Visualization
and Integrated Discovery)
25 bioinformatics to identify rele-
vant biological processes/functions from expression data
captured by transcriptome analysis. Based on gene ontology,
differentially expressed genes were grouped by scoring the
statistical signiﬁcance of predeﬁned functional gene groups
according to their functional similarity.
We used Ingenuity Pathway Analysis software (IPA,
http://www.ingenuity.com) to analyze probable network/path-
way and functional group enrichment. For each data set, the
selected genes were uploaded into the IPA application. Net-
works were then algorithmically generated based on gene–
gene connectivity.
ZR and forestomach carcinogenesis in ZD:Cox-2
2/2 mice
This mouse study was approved by the Thomas Jefferson Univer-
sity Animal Use Committee. Thirty-nine 4-week old Cox-2
 / 
mice were fed a ZD diet to form the ZD:Cox-2
 /  group. After
4 weeks, the mice received three intragastric doses of NMBA
(2 mg/kg body weight, twice weekly), a regimen that produced a
high tumor outcome in ZD:Cox-2
 /  mice.
16 A day after
the 3rd dose, 18 mice were switched to a ZS diet to form the
ZR:Cox-2
 /  group, which were given an intragastric dose of Zn
gluconate weekly for 14 weeks (0.04 mg Zn). The remaining
ZD:Cox-2
 /  mice continued on ZD diet. All mice were sacri-
ﬁced for tumor outcome analysis at 14 weeks of Zn intervention.
Tumor analysis
At autopsy, tongue, esophagus and forestomach were excised.
Tumors greater than 0.5 mm were mapped. Tissues were forma-
lin-ﬁxed and parafﬁn-embedded for histopathologic/IHC studies.
Quantitative reverse transcriptase-polymerase chain
reaction
Quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) was performed using the comparative Ct method
and predesigned probes on 7300 Real-time PCR System
(Applied Biosystems, Foster City, CA). GAPDH was used to
normalize RNA samples.
14
Immunoblotting
Proteins were separated by 10–14% Tris-HCl gel (Bio-Rad,
Hercules, CA) as described.
13 GAPDH (Calbiochem, San
Diego, CA) was used as a loading control.
IHC
IHC was performed as described.
13–16 The following antisera
were used: mouse anti-proliferating cell nuclear antigen
(PCNA) monoclonal (Thermo Scientiﬁc); rat anti-S100A8
monoclonal, goat anti-S100A9 monoclonal, and rat anti-re-
ceptor for advanced glycation end-products (RAGE) mono-
clonal (R&D Systems, Minneapolis, MN); rabbit anti-nuclear
factor (NF)-jB p65 polyclonal (Abcam, Cambridge, MA),
rabbit anti-NF-jB phospho-p65 (serine 276) polyclonal and
rabbit anti-cyclin D1 monoclonal antiserum (Cell Signaling,
Danvers, MA) or rabbit anti-p53 polyclonal antiserum
(detects both mutated and wild-type proteins) (Leica Micro-
systems, Bannockburn, IL). Protein was localized by incuba-
tion with 3-amino-9-ethylcarbazole substrate-chromogen
(AEC) (Dako, Carpinteria, CA) or 3,30-diaminobenzidine tet-
rahydrochloride (DAB; Sigma-Aldrich, St. Louis, MO).
Immunoreactive scores were calculated by multiplying the
percentage of positive cells by the grade of staining inten-
sity.
15 The percentage of positive cells was evaluated as fol-
lows: 0 ¼ 0–5%, 1 ¼ 6–25%, 2 ¼ 26–50%, 3 ¼ 51–75% and
4 ¼ 76–100%. The intensity of immunostaining was graded
as follows: 0 ¼ none, 1 ¼ weak, 2 ¼ moderate and 3 ¼
intense. The PCNA labeling index (%) was calculated by
dividing the number of PCNA-labeled nuclei by the total
number of cells counted.
Zn measurement
Hair Zn content was determined by atomic absorption spec-
trometry.
16 Invariably, Zn levels were signiﬁcantly lower in
ZD than ZS samples. As examples, hair Zn levels were signif-
icantly lower in ZD:Cox-2
 /  than ZS:Cox-2
 /  mice at 10
weeks (array study) [130 lg/g (95% conﬁdence interval [CI]
¼ 124–135) vs. 172 lg/g (95% CI ¼ 165–179), p ¼ 0.002, n
¼ 10/group) and at 26 weeks (NQO study); 111 lg/g (95%
CI ¼ 99–122) vs. 157 lg/g (95% CI ¼ 146–168), n ¼ 14
mice/group, p < 0.001].
Statistical analysis
Tumor multiplicity was analyzed by two-way analysis of var-
iance (ANOVA). Differences among the groups were assessed
using the Tukey-HSD post hoc t-tests for multiple compari-
sons. Tumor and carcinoma incidence rates were assessed by
Fisher’s exact test. CIs for the differences in incidence rates
were calculated using the Wilson Score Method.
26 Statistical
tests were two-sided and considered signiﬁcant at p < 0.05.
Results
ZD enhances tongue carcinogenesis in Cox-2 deﬁcient
mice
NQO is a DNA adduct-forming agent that serves as a surro-
gate of tobacco exposure.
27 Nutritionally complete WT mice
exposed to 10 ppm of NQO for 50 weeks did not develop
tongue lesions.
28 At a high concentration of 100 ppm,
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geal tumors.
29
To investigate whether a Zn-deﬁcient condition eliminates
the antitumor effect of genetic Cox-2 disruption in NQO-
induced tongue carcinogenesis as it does in NMBA-induced
forestomach carcinogenesis,
16 Cox-2
 / , Cox-2
þ/ , and WT
mice on ZD vs. ZS diets were exposed to drinking water con-
taining 20 ppm of NQO for 19 weeks followed by 30 ppm
for another 7 weeks. At week 26, ZS:Cox-2
 /  and ZS:Cox-
2
þ/  mice had signiﬁcantly lower tongue/forestomach tumor
incidence than ZS:WT littermates (Fig. 1a, statistical data in
Supporting Information Table 1). This result is consistent
with those reported in nutritionally complete mice showing
that Cox-2 absence protects against carcinogenesis.
16,21,30
Conversely, in ZD mice, genetic Cox-2 did not protect against
carcinogenesis. ZD:Cox-2
 /  mice had signiﬁcantly greater
tongue/esophageal tumor incidence than ZD:WT littermates,
and ZD:Cox-2
 /  and ZD:Cox-2
þ/  mice showed signiﬁ-
cantly higher tumor multiplicity in all three sites (tongue,
esophagus and forestomach) than ZD:WT controls (inci-
dence, Fig. 1a; multiplicity, Fig. 1b, Supporting Information
Table 1). In addition, ZD led to large tumor size (Fig. 1c)
and malignant progression of tongue/esophageal/forestomach
tumors in ZD:Cox-2
 /  and ZD:Cox-2
þ/  mice compared
with ZD:WT mice (Fig. 1d), with statistical signiﬁcance
achieved for tongue SCC (ZD:Cox-2
 /  vs. ZD:WT, 35.7% [5
of 14] vs. 0% [0 of 19], p < 0.01; ZD:Cox-2
þ/  vs. ZD:WT,
32.6% [15 of 46] vs. 0% [0 of 19], p < 0.01) (Fig. 1a,S u p -
porting Information Table 1). These data demonstrated that
prolonged ZD abolished the antitumor effect of COX-2
blockade in tongue tumor prevention and elicited tumors in
multiple sites with progression to malignancy.
Among mice of the same genetic background, tongue tu-
mor incidence/multiplicity and carcinoma incidence were sig-
niﬁcantly higher in homozygous ZD:Cox-2
 /  vs.Z S : Cox-2
 / 
or heterozygous ZD:Cox-2
þ/  vs. ZS:Cox-2
þ/  mice, but
not in ZD:WT vs. ZS:WT mice (Fig. 1a and b, Supporting In-
formation Table 1), demonstrating that combined ZD and
Cox-2 ablation led to a worse tumor outcome. These results
are consistent with and extend our previous study in NMBA-
induced forestomach carcinogenesis.
16
ZD per se induces an inﬂammatory gene signature in
ZD:Cox-2
2/2 forestomach
To test the hypothesis that ZD promotes carcinogenesis by
activating cancer pathways not inhibited by genetic Cox-2
ablation, we performed transcriptome proﬁling of forestom-
ach mucosa from ZD:Cox-2
 / , ZS:Cox-2
 / , ZD:WT and
ZS:WT mice (n ¼ 4/group). We used forestomach rather
than tongue because its epithelia can be readily separated
from the muscularis layers without enzymatic digestion.
First, we examined the effect of ZD on gene expression
changes in Cox-2
 /  forestomach and WT forestomach. By
using a cutoff of p   0.05 and 2-fold difference in expression
levels, we found 314 dysregulated probe sets in ZD:Cox-2
 / 
vs. ZS:Cox-2
 /  forestomach (Supporting Information Table
2) but only 67 in ZD:WT vs. ZS:WT forestomach (Support-
ing Information Table 3). Thus, dietary ZD causes more
extensive changes in gene expression in Cox-2
 /  than WT
forestomach. A cohort of 36 genes, including the proinﬂam-
mation mediators S100a8/a9, small proline-rich protein 2
Sprr2f/2h, and keratins Krt6a/8/19, was common to both
class comparisons, indicating that these genes were induced
by ZD regardless of genotype.
Next, we compared the effect of Cox-2 deletion on gene
expression changes in ZD forestomach and in ZS forestom-
ach. With a cutoff of 2-fold difference, we found 90 dysregu-
lated genes in ZD:Cox-2
 /  vs. ZD:WT forestomach (Sup-
porting Information Table 4) but only 17 in ZS:Cox-2
 /  vs.
ZS:WT forestomach (Supporting Information Table 5). There
are no common changes in gene expression between these
two class comparisons, and Cox-2 deletion causes fewer
changes in ZS than ZD forestomach.
Our qRT-PCR data validated a total 12 selected genes for
ZD:Cox-2
 /  vs. ZS:Cox-2
 /  forestomach; six genes for
ZD:WT vs. ZS:WT, 7 genes for ZD:Cox-2
 /  vs. ZD:WT, and
three genes for ZS:Cox-2
 /  vs. ZS:WT forestomach (Sup-
porting Information Table 6).
Among the four class comparisons (Supporting Informa-
tion Tables 2–5), ZD:Cox-2
 /  vs. ZS:Cox-2
 /  forestomach
showed the most extensive changes in gene expression, a
result consistent with their divergent tumorigenic potential
16
(Fig. 1). Hierarchical clustering analysis of 45,000 transcripts
revealed distinct expression patterns (Fig. 2a) between hyper-
plastic ZD:Cox-2
 /  and nonproliferative ZS:Cox-2
 /  forest-
omach (Fig. 2b). By further ﬁltering the data using a cutoff
of 4-fold difference, we identiﬁed a group of 63 genes (62
up- and 1 downregulated; Table 1). The most upregulated
genes are implicated in the following processes: Sprr2h/2f and
Krt6a/16 in cytoskeleton metabolism and S100a8 and S100a9
(upregulated 24- and 2.2-fold) in inﬂammatory/defense/
immune responses. Interestingly, S100a8/a9 were also upreg-
ulated 4.2- and 2.4-fold in ZD:WT vs. ZS:WT forestomach
(Supporting Information Table 3). Because S100a8/a9 overex-
pression is associated with ZD-induced rat esophageal pre-
neoplasia,
14 the data that these same genes were upregulated
by ZD in hyperplastic ZD:Cox-2
 /  forestomach indicate that
they are relevant ZD-induced markers in early forestomach
carcinogenesis.
DAVID bioinformatics reveals overrepresentation of
inﬂammatory processes
To deﬁne the biological signiﬁcance of the large lists of dif-
ferentially expressed genes captured by our transcriptome
proﬁling (Supporting Information Tables 2–5), we performed
gene ontology functional group analyses for the four class
comparisons using DAVID resources.
25 In preneoplastic
ZD:Cox-2
 /  vs. ZS:Cox-2
 /  forestomach (Supporting Infor-
mation Table 7a), we found signiﬁcantly overrepresented bio-
logical processes only among the upregulated genes; including
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Int. J. Cancer: 129, 331–345 (2011) V C 2010 UICCFigure 1. Zn-deﬁciency abolishes the antitumor effects of genetic Cox-2 blockade in NQO-induced tongue carcinogenesis. a. Tumor
incidence (%). ZS:Cox-2
 /  and ZS:Cox-2
þ/  mice had signiﬁcantly lower tongue/forestomach tumor incidence than ZS:WT mice (*p <
0.05, ***p < 0.001). By contrast, ZD:Cox-2
 /  had greater tongue/esophagus tumor incidence than ZD:WT mice (*p < 0.05). ZD:Cox-2
 / 
and ZD:Cox-2
þ/  mice had greater tongue/esophagus/forestomach tumor incidence than ZS:Cox-2
 /  and ZS:Cox-2
þ/  mice (††p < 0.01,
†††p < 0.001). Carcinoma incidence (%): ZD:Cox-2
 /  and ZD:Cox-2
þ/  mice had higher tongue carcinoma incidence than ZD:WT mice (**p
< 0.01). Also, ZD:Cox-2
 /  and ZD:Cox-2
þ/  mice had greater tongue carcinoma incidence than respective ZS:Cox-2
 /  and ZS:Cox-2
þ/ 
(††p < 0.01, †††p < 0.001). b. Tumor multiplicity (error bars ¼ SEM). ZD:Cox-2
 /  and ZD:Cox-2
þ/  mice had signiﬁcantly more tumors/
site (tongue, esophagus, forestomach) than ZD:WT counterpart (*p < 0.05, **p < 0.01, and ***p < 0.001). In addition, ZD:Cox-2
 /  and
ZD:Cox-2
þ/  mice had signiﬁcantly more tumors/site than ZS:Cox-2
 /  and ZS:Cox-2
þ/  counterpart (††p < 0.01, †††p < 0.001). c. Gross
anatomy of tongue/esophagus/forestomach. Scale bars, 5 mm. d. H&E-stained sections showing tongue/esophageal/forestomach
carcinomas from ZD:Cox-2
 /  and ZD:Cox-2
þ/  and thickened mucosa from ZS:Cox-2
 /  mice. Scale bar ¼ 100 lm. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]in particular, response to external stimulus comprising
S100a8/a9 and 14 genes (p ¼ 3.98E-004) and response to
stimulus comprising S100a8/a9 and 34 genes (p ¼ 5.04E-
004). Thus, DAVID supports the premise that S100a8/a9 are
relevant markers associated with ZD-induced hyperplasia in
ZD:Cox-2
 /  forestomach. Similarly, in ZD:WT vs. ZS:WT
(Supporting Information Table 7b) and ZD:Cox-2
 /  vs.
ZD:WT forestomach (Supporting Information Table 7c), sig-
niﬁcantly overrepresented processes were found only among
the upregulated genes, including cytoskeleton and chemotaxis
processes. By contrast, in ZS:Cox-2
 /  vs. ZS:WT forestom-
ach (Supporting Information Table 7d), signiﬁcantly overre-
presented processes were found only among the downregu-
lated genes that negatively modulated cell cycle and
cytoskeleton processes. Together, the data revealed that die-
tary ZD and sufﬁciency led to distinct regulated processes in
proliferation in Cox-2
 /  forestomach, a ﬁnding consistent
with the divergent tumorigenic potential of ZD:Cox-2
 /  vs.
ZS:Cox-2
 /  forestomach.
IPA reveals a NF-jB—centric network
To understand gene expression interactions in ZD:Cox-2
 / 
vs. ZS:Cox-2
 /  forestomach (Table 1) in the context of sig-
naling pathways, we performed pathway analysis using IPA.
We identiﬁed a nuclear factor (NF)-jB centric network of 35
genes, with 60% of the genes (21 of 35) from the upregulated
genes that included S100a8 (Fig. 2c). Because NF-jBi sa
transcription factor that regulates immune responses/cell pro-
liferation and it is a link between inﬂammation and cancer
development/progression,
31 our result that NF-jB showed
connectivity to S100a8 predicted activation of a S100A8-NF-
jB inﬂammatory pathway in ZD:Cox-2
 /  forestomach.
ZD activates S100A8 inﬂammatory signaling in
preneoplastic ZD:Cox-2
2/2 forestomach
We focused our study on S100A8 and its heterodimeric
partner S100A9 because of their role in inﬂammation and
cancer,
14,32 and their prominence among ZD-induced
Figure 2. Expression proﬁling of forestomach mucosa. a. Dendrogram illustrating clustering of  45,000 transcripts in ZD:Cox-2
 /  and
ZS:Cox-2
 /  forestomach (n ¼ 4 mice/group). Red and green denote up- and downregulated genes. b. H&E- and PCNA-stained (red, AEC)
hyperplastic ZD:Cox-2
 /  forestomach and ZS:Cox-2
 /  forestomach. Scale bar ¼ 50 lm. c. IPA uncovers a NF-jB network from the
upregulated genes (red) in ZD:Cox-2
 /  vs. ZS:Cox-2
 /  forestomach. IPA inserts genes (white) to complete the network. Solid and dash
lines reﬂect, respectively, direct and indirect relationships among the genes. [Color ﬁgure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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-/- vs non-proliferative ZS:Cox-2
-/- mouse forestomach
Gene symbol Affymetrix id p FDR
Fold-change,
ZD:Cox-2
-/-
vs ZS:Cox-2
-/- Gene title Function
62 Upregulated genes associated with dietary ZD
Sprr2h 1422240_s_at 0.00005 0.17 64 Small proline-rich protein
2H
Keratinocyte
differentiation
Sprr2f 1449833_at 0.00009 0.21 49 small proline-rich protein
2F
epithelial to mesenchymal
transition
Krt16 1448932_at 0.00006 0.17 47 Keratin 16 Intermediate ﬁlament
cytoskeleton
Krt6a 1422784_at 0.00056 0.26 45 Keratin 6A Intermediate ﬁlament
organization
Chi3l4 1425450_at 0.00431 0.28 39 chitinase 3-like 4 inﬂammatory response
Defb3 1421806_at 0.00000 0.02 29 Defensin beta 3 Defense response
Dmbt1 1418287_a_at 0.00015 0.23 27 Deleted in malignant brain
tumors 1
Positive regulation of
epithelial cell
*S100a8 1419394_s_at 0.00000 0.06 24 S100 calcium binding
protein A8 (calgranulin A)
Chemotaxis
Mcpt2 1449989_at 0.00071 0.26 23 Mast cell protease 2 Proteolysis
Pigr 1450060_at 0.00259 0.27 17 Polymeric immunoglobulin
receptor
Receptor activity
U46068 1423719_at 0.00309 0.28 17 cDNA sequence U46068 lipid binding
Chi3l3 1419764_at 0.00096 0.26 17 Chitinase 3-like 3 Inﬂammatory response
Ltf 1450009_at 0.00096 0.26 15 Lactotransferrin Cellular iron ion
homeostasis
LOC67527 1431213_a_at 0.00028 0.26 14 Murine leukemia retrovirus NA
Mcpt1 1422352_at 0.00043 0.26 14 Mast cell protease 1 Proteolysis
A130040M12Rik 1428909_at 0.00042 0.26 13 RIKEN cDNA A130040M12
gene
NA
1190003M12Rik 1429286_at 0.00310 0.28 12 RIKEN cDNA 1190003M12
gene
NA
Tff2 1422448_at 0.00984 0.30 12 Trefoil factor 2 (spasmolytic
protein 1)
Mucosal defense
Krt17 1423227_at 0.00100 0.26 11 Keratin 17 Intermediate ﬁlament
organization
Agr2 1419268_at 0.00242 0.26 10 Anterior gradient 2
(Xenopus laevis)
Mucosal defense
2310046K23Rik 1454264_at 0.00317 0.28 9.3 RIKEN cDNA 2310046K23
gene
NA
Krt19 1417156_at 0.00878 0.30 8.9 Keratin 19 Intermediate ﬁlament
Clca3 1416306_at 0.01335 0.32 8.3 Chloride channel calcium
activated 3
Calcium ion transport
Anxa10 1449426_a_at 0.03486 0.35 8.2 Annexin A10 calcium-dependent
phospholipid binding
Defb4 1419600_at 0.00152 0.26 8.1 Defensin beta 4 Defense response
Stfa1 1435761_at 0.00228 0.26 8.0 Steﬁn A1 Cysteine protease
inhibitor activity
Cﬁ 1418724_at 0.00192 0.26 7.9 Complement component
factor i
Innate immune response
Spp1 1449254_at 0.00022 0.23 7.9 Secreted phosphoprotein 1 Cell adhesion
Krt18 1448169_at 0.00374 0.28 7.9 Keratin 18 Intermediate ﬁlament
C
a
n
c
e
r
G
e
n
e
t
i
c
s
Wan et al. 337
Int. J. Cancer: 129, 331–345 (2011) V C 2010 UICCTable 1. Gene expression signature in hyperplastic ZD:Cox-2
-/- vs non-proliferative ZS:Cox-2
-/- mouse forestomach (Continued)
Gene symbol Affymetrix id p FDR
Fold-change,
ZD:Cox-2
-/-
vs ZS:Cox-2
-/- Gene title Function
Krt8 1420647_a_at 0.01074 0.31 7.1 Keratin 8 Intermediate ﬁlament
Idi2 1440852_at 0.02160 0.33 6.8 Isopentenyl-diphosphate
delta isomerase 2
Isoprenoid biosynthetic
process
Crisp1 1416325_at 0.00134 0.26 6.7 Cysteine-rich secretory
protein 1
NA
Cftr 1420579_s_at 0.00236 0.26 6.6 Cystic ﬁbrosis
transmembrane
conductance regulator
homolog
Ion transport
Igh 1421653_a_at 0.00387 0.28 6.0 Immunoglobulin heavy
chain complex
Immune response
Tspan8 1424649_a_at 0.02129 0.33 5.9 Tetraspanin 8 Signal transduction
Ctse 1418989_at 0.03346 0.35 5.9 Cathepsin E Aspartyl protease activity
Dsc2 1421156_a_at 0.00036 0.26 5.9 Desmocollin 2 Cell adhesion
2610528A11Rik 1435639_at 0.00555 0.28 5.8 RIKEN cDNA 2610528A11
gene
NA
Iﬁ202b 1421551_s_at 0.00020 0.23 5.6 Interferon activated gene
202B
Proteolysis
Klk1 1415837_at 0.00503 0.28 5.5 Kallikrein 1 Proteolysis
Ghrl 1448980_at 0.02208 0.33 5.5 Ghrelin Dendrite development
Krt20 1426284_at 0.00750 0.29 5.4 Keratin 20 Cellular response to
stress
Gcnt3 1440409_at 0.01574 0.32 5.4 Glucosaminyl (N-acetyl)
transferase 3, mucin type
Transferase activity
Cldn2 1417231_at 0.00229 0.26 5.3 Claudin 2 Calcium-independent
cell-cell adhesion
Cldn7 1448393_at 0.00018 0.23 4.8 Claudin 7 Structural molecule
activity
Cldn18 1449428_at 0.04404 0.36 4.7 Claudin 18 Tight junction
1200016E24Rik 1435137_s_at 0.00003 0.16 4.7 RIKEN cDNA 1200016E24
gene
NA
Krt6b 1422588_at 0.00143 0.26 4.6 Keratin 6B Intermediate ﬁlament
Ceacam1 1425538_x_at 0.00140 0.26 4.6 Carcinoembryonic
antigen-related cell
adhesion molecule 1
Positive regulation of MAP
kinase activity
Scd2 1415824_at 0.00166 0.26 4.5 Stearoyl-Coenzyme A
desaturase 2
Lipid metabolic process
Muc1 1449199_at 0.01496 0.32 4.4 Mucin 1, transmembrane Cytoskeleton
Lcn2 1427747_a_at 0.02630 0.34 4.4 Lipocalin 2 Transporter activity
Prom1 1419700_a_at 0.01526 0.32 4.3 Prominin 1 maintaining stem cell
properties
Anxa8 1417732_at 0.02923 0.34 4.2 Annexin A8 Calcium-dependent
phospholipid binding
Aqp5 1418818_at 0.00460 0.28 4.2 Aquaporin 5 Transporter activity
Muc4 1438555_x_at 0.01402 0.32 4.1 Mucin 4 Cell adhesion
Tcrb-J 1452205_x_at 0.00043 0.26 4.1 T-cell receptor beta, joining
region
NA
C130090K23Rik 1426268_at 0.00725 0.29 4.1 RIKEN cDNA C130090K23
gene
NA
Ppbp 1418480_at 0.00167 0.26 4.0 Pro-platelet basic protein Chemotaxis
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 /  forestomach (Sup-
porting Information Table 7a). S100a8/a9 genes encode the
S100 family member calcium binding proteins. Interaction of
S100A8/A9 ligands with their receptor RAGE triggers an in-
tracellular NF-jB signaling cascade.
14,32
To determine if there is a link between S100A8 overexpres-
sion and downstream NF-jB signaling in preneoplastic
ZD:Cox-2
 /  vs. ZS:Cox-2
 /  forestomach as predicted by IPA
(Fig. 2c), we analyzed expression of ﬁve signaling markers,
namely, S100A8, S100A9, the RAGE receptor, NF-jB p65, and
cyclin D1, by IHC. The cyclin D1 gene is a target of NF-jB acti-
vation.
33 IHC showed that all ﬁve markers were strongly
expressed in hyperplastic ZD:Cox-2
 /  forestomach but weakly
expressed in nonproliferative ZS:Cox-2
 /  forestomach (Fig.
3a). The semi-quantitative mean immunoreactive scores of
S100A8 and S100A9 protein were signiﬁcantly higher in
ZD:Cox-2
 /  than ZS:Cox-2
 /  forestomach [S100A8, 7.3 (95%
CI ¼ 5.5–9.1) vs. 1.6 (95% CI ¼ 0.9–2.3), p < 0.001; S100A9,
6.6 (95% CI ¼ 3.7–9.5) vs. 1.5 (95% CI ¼ 0.9–2.1), p < 0.001, n
¼ 8 mice/group). In addition, ZD:Cox-2
 /  forestomach over-
expressed phospho-NF-jB p65, indicating activation and nu-
clear translocation of NF-jB p65 (Supporting Information Fig.
1). These data show that at the earliest stages of forestomach
carcinogenesis ZD activates an alternative S100A8 inﬂamma-
tory pathway not affected by genetic Cox-2 inhibition.
ZR reverses S100A8 inﬂammatory signaling and
hyperplasia in ZD:Cox-2
2/2 forestomach
Because ZR attenuates inﬂammation and reverses hyperplasia
in early rat esophageal carcinogenesis,
14 we investigated this
effect in ZD:Cox-2
 /  mice one week after switching to a ZS
diet. In contrast to ZD:Cox-2
 /  forestomach that showed
strong expression of all ﬁve S100A8 inﬂammatory signaling
markers (Fig. 3a [left column]), ZR:Cox-2
 /  mouse forest-
omach had reduced or absent immunostaining of the same
ﬁve markers (Fig. 3b). Additionally, qRT-PCR analysis shows
that S100a8 and S100a9 mRNA expression was signiﬁcantly
reduced in ZR:Cox-2
 /  vs. ZD:Cox-2
 /  forestomach (Fig.
3c).
In addition, we determined the rate of cell proliferation in
ZR:Cox-2
 /  vs. ZD:Cox-2
 /  forestomach by quantitative
PCNA-lHC (PCNA: Fig. 3bv s .2 b). PCNA is an endogenous
cell proliferation marker. The PCNA-labeling index (%) was
signiﬁcantly lower in ZR:Cox-2
 /  than ZD:Cox-2
 /  forest-
omach (Fig. 3d). Together, these data (Fig. 3b–d) document
that ZR effectively attenuated S100A8 inﬂammation and
reversed the hyperplastic ZD:Cox-2
 /  phenotype.
ZD upregulates S100a8/a9 expression in preneoplastic
ZD:Cox-2
2/2 tongue
To determine whether ZD:Cox-2
 /  tongue, which shows
high tumorigenic potential as does ZD:Cox-2
 /  forestom-
ach
16 (Fig. 1), also overexpresses the proinﬂammation genes
S100a8/a9 discovered in forestomach, we determined S100a8/
a9 mRNA and protein expression levels in tongue and forest-
omach from the four mouse groups (proﬁling studies) by
qRT-PCR and immunoblotting. As in forestomach, S100a8/
a9 mRNA expression was strongest in ZD:Cox-2
 /  tongue,
followed by ZD:WT tongue, and negligible in ZS:Cox-2
 / 
and ZS:WT tongue (Fig. 3e, top). In parallel, S100A8/A9
Table 1. Gene expression signature in hyperplastic ZD:Cox-2
-/- vs non-proliferative ZS:Cox-2
-/- mouse forestomach (Continued)
Gene symbol Affymetrix id p FDR
Fold-change,
ZD:Cox-2
-/-
vs ZS:Cox-2
-/- Gene title Function
Igk-V1 1427660_x_at 0.00994 0.30 4.0 Immunoglobulin kappa
chain variable 1 (V1)
NA
AA467197 1434046_at 0.01196 0.31 4.0 Expressed sequence
AA467197
NA
F5 1418907_at 0.00510 0.28 4.0 Coagulation factor V Blood circulation
EG668468 1451699_at 0.00347 0.28 3.7 predicted gene, EG668468 NA
100042999 1437258_at 0.00395 0.28 3.7 Predicted gene,
100042999
NA
Chad 1420569_at 0.01608 0.32 3.7 Chondroadherin Protein binding
Slc44a4 1416596_at 0.00621 0.29 3.6 Solute carrier family 44,
member 4
Cellular component
**S100a9 1448756_at 0.00329 0.28 2.2 S100 calcium binding
protein A9 (calgranulin B)
Chemotaxis
1 Downregulated gene associated with dietary ZD
Cyp1b1 1416612_at 0.00285 0.28 0.16 Cytochrome P450, family 1,
subfamily b, polypeptide 1
Toxin metabolic process
The list includes genes that are signiﬁcantly upregulated or downregulated  4-fold in ZD:Cox-2
-/- vs ZS:Cox-2
-/- mouse forestomach. Multiple sets
for the same gene are excluded.
**S100a9 (up 2.2-fold), a heterodimer of *S100a8, is included for reference.
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 /  tongue
and forestomach but weak or absent in similar tissues of
other mouse groups (Fig. 3e, bottom). These data suggests
that in tongue and forestomach ZD activates similar inﬂam-
matory pathways that are not affected by COX-2 inhibition.
Activation of S100A8 and p53 inﬂammatory pathways
accompanies malignant tumor progression in ZD:Cox-2
2/2
and ZD:Cox-2
1/2 mice
We then went on to investigate whether during malignant
tongue/forestomach tumor progression (Fig. 1) S100A8
inﬂammatory signaling is in fact activated. In addition, we
determined whether these carcinomas overexpress PCNA and
p53 protein, two prognostic factors in human oral cancers.
34,35
The p53 tumor suppressor gene is mutated in approximately
50% of all human cancers, including oral-esophageal cancers
36
and divergent carcinogenic pathways mediated separately by
NF-jB and p53 were reported in oral cancer.
37 Using IHC we
examined expression of seven markers: PCNA, p53, and ﬁve
S100A8—NF-jB signaling markers (S100A8, S100A9, RAGE,
NF-jBp65 and cyclin D1). We analyzed a total of 15 ZD:Cox-
2
 /  tongue SCC and 6 ZD:Cox-2
þ/  forestomach SCC, as
well as non-neoplastic ZS:Cox-2
 /  tongue and ZS:Cox-2
þ/ 
forestomach (n ¼ 10/group).
ZD:Cox-2
 /  tongue SCC and ZD:Cox-2
þ/  forestomach
SCC showed high proliferative activity with abundant PCNA-
positive nuclei in tumor areas and prominent accumulation
of intensely stained p53-positive nuclei. Concurrently, these
carcinomas displayed strong co-overexpression of all ﬁve
S100A8—NF-jB signaling markers (Fig. 4). In addition, these
carcinomas overexpressed phospho-NF-jB p65 (Supporting
Information Fig. 1), indicating activation and nuclear translo-
cation of NF-jB p65. Collectively, these data demonstrate
that under complete or partial genetic Cox-2 ablation, ZD
stimulated RAGE-S100A8 inﬂammatory signaling cancer-and
p53-associated response pathways, thereby driving malignant
Figure 3. Zn modulates S100A8/A9 expression in Cox-2
 /  mouse forestomach and tongue. a. Zn-deﬁciency activates a RAGE-S100A8/9
inﬂammation pathway in ZD:Cox-2
 /  forestomach. Immunostaining of 5 markers (S100A8, S100A9, RAGE, NF-jB p65, and cyclin D1) in
ZD:Cox-2
 /  vs. ZS:Cox-2
 /  forestomach (n ¼ 8 mice/group, DAB, brown). Scale bar ¼ 25 lm. b. Zn-replenishment attenuates S100A8
inﬂammation in ZR:Cox-2
 /  forestomach (eight mice were analyzed). H&E, IHC of PCNA and the ﬁve markers (red, AEC). Scale bars ¼ 50
lm. c. qRT-PCR analysis of S100a8/a9 mRNA expression in ZR:Cox-2
 /  vs. ZD:Cox-2
 /  forestomach (n ¼ 6 mice/group). d. PCNA-labeling
index (%) in ZR:Cox-2
 /  vs. ZD:Cox-2
 /  forestomach (error bars ¼ SEM; n ¼ 6 mice/group). e. Upper panels: qRT-PCR analysis of
S100a8/a9 mRNA expression in tongue/forestomach from four mouse groups (n ¼ 6 mice/group). Lower panels: immunoblotting of
S100A8/A9 protein expression in tongue/forestomach (each band represents pooled samples from three mice). [Color ﬁgure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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Int. J. Cancer: 129, 331–345 (2011) V C 2010 UICCFigure 4. Zn-deﬁciency activates RAGE-S100A8/9 signaling and p53 accumulation in ZD:Cox-2
 /  and ZD:Cox-2
þ/  tongue/forestomach
carcinomas. IHC of 7 markers: PCNA, p53, S100A8, S100A9, RAGE, NF-jB p65 and cyclin D1 (red, AEC; brown, DAB; black, DAB with cobalt
chloride). Scale bars, 50 lm (PCNA); 25 lm (all other markers). [Color ﬁgure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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COX-2 blockade.
In sharp contrast, non-neoplastic ZS:Cox-2
 /  tongue and
ZS:Cox-2
þ/  forestomach showed basal cell proliferation with
isolated occurrence of p53 protein, as well as low levels of
expression of the same ﬁve S100A8 signaling markers (Fig.
4), providing evidence that inﬂammatory pathways were not
activated under conditions of COX-2 pathway blockade and
ZS that protected against carcinogenesis.
ZR attenuates the inﬂammation and restores the antitumor
effect of COX-2 blockade in cancer prevention
Finally, we investigated whether replenishing Zn can restore
the antitumor effect of COX-2 blockade in tumor prevention.
In a NMBA-induced forestomach carcinogenesis study, we
showed that 14 weeks after ZR, ZR:Cox-2
 /  mice had signif-
icantly lower forestomach tumor incidence and multiplicity
than ZD:Cox-2
 /  mice (Fig. 5a). In addition, S100a8/a9
mRNA expression was signiﬁcantly lower in ZR:Cox-2
 /  vs.
ZD:Cox-2
 /  forestomach (Fig. 5b); S100A8/A9 protein
expression was absent in ZR:Cox-2
 /  but strongly expressed
in ZD:Cox-2
 /  forestomach (Fig. 5c). Histopathologic and
IHC studies show that ZR:Cox-2
 /  forestomach mucosa was
typically thin, with PCNA-positive nuclei mainly in basal
cells and weak to negligible immunostaining of the 4 inﬂam-
mation-associated markers S100A8, S100A9, p53, and cyclin
D1 (Fig. 5d). In contrast, neoplastic ZD:Cox-2
 /  forestom-
ach was highly proliferative, with PCNA-positive nuclei in
Figure 5. Zn-replenishment reverses inﬂammatory responses and inhibits NMBA-induced forestomach carcinogenesis. a.T u m o rd a t a .b.q R T - P C Ra n a l y s i s
of S100a8/a9 mRNA expression in ZR:Cox-2
 /  and ZD:Cox-2
 /  forestomach (error bars ¼ SEM; n ¼ 6m i c e / g r o u p ) .c. Immunoblotting of S100A8/A9
protein expression in ZR:Cox-2
 /  and ZD:Cox-2
 /  forestomach. d. H&E and IHC of PCNA, p53, S100A8, S100A9 and cyclin D1, in ZR:Cox-2
 /  vs.
ZD:Cox-2
 /  forestomach (15 mice/group were analyzed). Scale bars, 100 lm( H & E ) ;5 0lm( P C N A ;Z D : Cox-2
 / : p53, S100A8, S100A9, cyclin D1); 25
lm( Z R : Cox-2
 /  : p53, S100A8, S100A9, cyclinD1). [Color ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
C
a
n
c
e
r
G
e
n
e
t
i
c
s
342 S100A8 inflammation in COX-2 blockade
Int. J. Cancer: 129, 331–345 (2011) V C 2010 UICCmany cell layers and strong overexpression of the same
inﬂammation-associated markers (Fig. 5d). Thus, ZR reverses
preneoplasia (Figs. 3b–3d), and effectively restores the antitu-
mor effect of Cox-2 ablation (Fig. 5) by attenuating the
inﬂammation.
Discussion
Increasingly cancers are treated with drugs that target speciﬁc
pathways shown to be of pathogenetic signiﬁcance. Our study
shows that the antitumor effect of genetic disruption of Cox-
2 in tongue cancer prevention is bypassed by Zn depletion
(Fig. 1), owing to activation of an alternative proneoplastic
pathway that is not affected by COX-2 inhibition. Using a
combination of techniques that included expression proﬁling,
bioinformatics and investigation of identiﬁed markers in
ZD:Cox-2
 /  mouse models of oral-esophageal cancers, our
data document a mechanism for the inability of COX-2
blockade to prevent tumor growth under ZD conditions.
The hyperplastic ZD:Cox-2
 /  vs. ZS:Cox-2
 /  forestom-
ach has a distinct signature (Table 1). The pro-inﬂammation
mediators S100a8 and S100a9 are upregulated 24-fold and
2.2-fold. In addition, the typical genes of the corniﬁed enve-
lope Sprr2h/2f and Krt6A/16/17/8/20 are upregulated 64- to
5.5-fold. Because simultaneous upregulation of S100A8/A9,
SPRR2 and KRT6A/16/17 is a common feature of human
inﬂammatory skin diseases such as psoriasis
38 and atopic der-
matitis,
39 this same signature in ZD:Cox-2
 /  forestomach
indicates an association between inﬂammation and its highly
hyperplastic phenotype. Our conclusion that S100a8/a9 are
relevant ZD-induced markers belonging to an inﬂammatory
pathway that drives forestomach cell proliferation rather than
an epiphenomenon of this process or of dietary Zn-deﬁcit is
supported by DAVID bioinformatics (Table 7a).
S100A8/A9 have emerged as important markers for
inﬂammation-associated cancers.
32,40 They are overexpressed
in many human cancers,
32 including lung, colorectal, pros-
tate, skin cancer, as well as HPV18-infected oral SCC.
41 The
mechanistic role of S100A8/A9 in tumor biology is emerging.
In a mouse skin cancer model, Gebhardt et al.
42 provided
genetic evidence that S100A8/A9 binds to RAGE, and RAGE
signaling sustains skin inﬂammation and promotes tumori-
genesis. In the lung, S100A8/A9 induces the activation of se-
rum amyloid A that activates NF-jB inﬂammatory signaling
and facilitates metastasis.
43 In a colitis-induced mouse cancer
model, S100A8/A9 and RAGE augment carcinogenesis
44 and
in an inﬂammation-associated liver cancer model, S100A8/A9
are identiﬁed as NF-jB target genes and their overexpression
promotes malignant progression.
45 Conversely, blockade of
RAGE suppresses tumor growth and metastasis.
42,46
Our IHC data in ZD:Cox-2
 /  tongue and ZD:Cox-2
þ/ 
forestomach carcinomas (Fig. 4) demonstrate that under
complete or partial blockade of COX-2 pathway dietary ZD
activates an alternative cancer-associated RAGE-S100A8
inﬂammatory pathway. The ﬁnding that these same carcino-
mas showed high PCNA proliferative activity and prominent
accumulation of p53 protein indicates that additional inﬂam-
mation-associated cancer pathways are activated. The p53 tu-
mor suppressor gene is mutated in human oral and esopha-
geal cancer.
36 Mutated p53 protein has a prolonged half-life
that leads to its accumulation in the nucleus. In this regard,
human head and neck squamous cell cancer (HNSCC),
which is a highly inﬂammatory, proliferative and aggressive
cancer,
47 exhibits high levels of p53 expression, abundant cell
proliferative activity,
34,35 as well as divergent carcinogenic
pathways mediated separately by NF-jB and p53.
37
Chronic inﬂammation contributes to the development of
 20% of all human cancers. The causes of inﬂammation are
often unknown.
48 Our recent report in rat esophagus that di-
etary Zn regulates S100A8 expression and modulates the link
between S100A8-RAGE and downstream NF-jB/COX-2 pro-
vides the ﬁrst evidence that Zn has an inﬂammation-modu-
lating role in essophageal cancer initiation/reversal.
14 Here
we demonstrate that with COX-2 pathway blockade pro-
longed dietary ZD causes chronic inﬂammation in the
tongue/forestomach by activating alternative inﬂammatory
RAGE-S100A8/A9 and p53 response pathways, thereby fuel-
ing tumor progression and bypassing the antitumor effect of
Cox-2 deletion. These new data provide a likely mechanism
to explain the inefﬁcacy of such targeted cancer therapy in
oral-cancer patients, since many of these patients are fre-
quently Zn-deﬁcient.
4–7
Recent studies reported that Zn supplementation improves
clinical outcomes in patients receiving radiotherapy for
HNSCC,
49 as well as concomitant chemotherapy and radio-
therapy for advanced nasopharyngeal carcinoma.
50 The pres-
ent ﬁnding that ZR attenuates the inﬂammatory response
and restores the antitumor effect of COX-2 blockade has im-
portant clinical implications. Thus, stratiﬁcation of patients
by Zn status would be useful, and a personalized cancer ther-
apeutic paradigm that includes Zn may improve efﬁcacy.
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